Welcome to our dedicated page for Precision Biosciences news (Ticker: DTIL), a resource for investors and traders seeking the latest updates and insights on Precision Biosciences stock.
Precision BioSciences, Inc. reports developments for a clinical-stage gene editing company using its proprietary ARCUS platform to develop in vivo therapies for diseases with high unmet need. Company news centers on PBGENE-HBV for chronic hepatitis B and PBGENE-DMD for Duchenne muscular dystrophy, including clinical-program updates, regulatory clearances and designations, scientific-meeting presentations, and data from the ELIMINATE-B and FUNCTION-DMD studies.
Recurring updates also include quarterly financial results, cash runway commentary, business priorities, and equity-compensation grants under Nasdaq inducement-award rules. Precision describes ARCUS applications across gene elimination, excision, and insertion, with program-specific disclosures tied to viral DNA, cccDNA, defective-gene removal, and AAV delivery.
Precision BioSciences (Nasdaq: DTIL) reported new ELIMINATE-B trial data for PBGENE-HBV in chronic hepatitis B at EASL 2026. Liver biopsies showed a 1-log (10-fold) reduction in cccDNA-derived transcripts after two 0.4 mg/kg doses, with indels inactivating polymerase in the remaining <1% of cccDNA.
PBGENE-HBV achieved durable pgRNA loss in 100% of evaluable patients (n=6) and substantial HBsAg declines in all treated patients (n=15). Across 38 doses in 16 patients, no dose-limiting toxicities occurred; observed Grade 3 lab abnormalities and hypotension were reversible, with mitigation measures reducing severe events.
Precision BioSciences (Nasdaq: DTIL) will host an investor webcast on May 27, 2026, at 8:00 AM EDT. The event will feature Hepatitis B experts and company management discussing new biopsy and clinical data from the ongoing Phase 1 ELIMINATE-B trial of PBGENE-HBV in chronic hepatitis B.
The webcast follows late-breaking biopsy data presented at the European Association for the Study of the Liver (EASL) Congress 2026 in Barcelona. A replay and a separate news release with detailed clinical data will be available on the company’s investor website after the conference embargo lifts.
iECURE (NASDAQ:DTIL) reported preliminary results from the low-dose cohort of its OTC-HOPE trial of ECUR-506 in neonatal-onset OTC deficiency.
The first treated infant showed 18 months without HAEs and stopped standard care. Across three low-dose patients, annualized HAEs fell 57% and HACs 65%, with generally well-tolerated safety in seven dosed participants.
Precision BioSciences (Nasdaq: DTIL) reported new preclinical PBGENE-DMD data at the ASGCT 2026 meeting. Early-juvenile DMD mice showed up to 3x higher skeletal and 12x higher respiratory dystrophin restoration versus late-juvenile mice, with diaphragm up to 12% and intercostals up to 30%, supporting evaluation in boys aged 2–3 years within the Phase 1/2 FUNCTION-DMD trial.
iECURE (NASDAQ:DTIL) reported preliminary data from the ongoing OTC-HOPE trial of ECUR-506 in neonatal-onset ornithine transcarbamylase deficiency, covering 7 participants across three dose cohorts as of April 20, 2026.
71% (5/7) had no hyperammonemic crises (HACs) post-treatment and the annualized HAC rate fell about 52%, from ~3.12 to ~1.49 events per year. ECUR-506 was generally well tolerated, with no infusion-related reactions or thrombotic microangiopathy and no prophylactic immunosuppression. Asymptomatic Grade 2–3 transaminitis occurred in 5 of 7 participants and was controlled with reactive immunosuppression. One death from hypoxemic respiratory failure was assessed as unrelated to ECUR-506 and linked to underlying disease complications. These early data support continued evaluation of ECUR-506’s safety and clinical activity.
Precision BioSciences (NASDAQ: DTIL) reported Q1 2026 results and operational progress, highlighting $125.8 million in cash on March 31, 2026 and advancement of two wholly owned in vivo programs: PBGENE-HBV (ongoing ELIMINATE-B trial; late-breaking EASL poster) and PBGENE-DMD (FDA IND cleared, Fast Track, first site activated).
Q1 revenue was $10.8 million; net loss was $18.4 million, or $(0.75) per share. Company expects cash runway to support key data milestones through 2028.
Precision BioSciences (Nasdaq: DTIL) said it will publish first quarter 2026 financial results and provide a business update on May 5, 2026. The company is a clinical‑stage gene editing firm using its proprietary ARCUS platform to develop in vivo therapies for high‑unmet‑need diseases.
Precision BioSciences (Nasdaq: DTIL) activated Arkansas Children’s Hospital as the first clinical trial site and opened patient screening and enrollment for PBGENE-DMD in the Phase 1/2 FUNCTION-DMD study on April 29, 2026. PBGENE-DMD targets DMD mutations between exons 45 and 55 and will assess safety, tolerability, dystrophin expression, and functional outcomes in ambulatory patients.
Arkansas Children’s is a PPMD-certified Duchenne Care Center and an MDA Care Center; additional sites are being activated to expand enrollment.
iECURE (NASDAQ:DTIL) will present preliminary clinical data for ECUR-506 in neonatal-onset ornithine transcarbamylase (OTC) deficiency at ASGCT (May 11-15, 2026) and SIMD (May 17-20, 2026).
Oral data cover the first three dose cohorts (n=7) and report a decreased rate of hyperammonemic crises. A SIMD poster shows one-year post-treatment data for the first infant who achieved a complete clinical response with sustained discontinuation of standard-of-care therapies.
Precision BioSciences (Nasdaq: DTIL) announced an oral presentation of new preclinical PBGENE-DMD data at the ASGCT 2026 Annual Meeting, May 11-15 in Boston.
The abstract reports efficacy in early-juvenile mice and builds on prior updates showing durable functional improvement in a humanized DMD mouse model. Presentation: May 14, 2026 at 8:45 a.m. ET; Presenter: Adam Michler Ph.D., DMD Research Lead; Session: Emerging molecular therapeutic strategies for muscular dystrophies.